On Friday, Janux Therapeutics Inc (NASDAQ: JANX) was -4.86% drop from the session before settling in for the closing price of $27.75. A 52-week range for JANX has been $22.48 – $71.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -67.90% over the last five years. When this article was written, the company’s average yearly earnings per share was at -52.21%. With a float of $49.54 million, this company’s outstanding shares have now reached $59.17 million.
The firm has a total of 81 workers. Let’s measure their productivity. In terms of profitability, gross margin is 94.58%, operating margin of -1216.61%, and the pretax margin is -832.71%.
Janux Therapeutics Inc (JANX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Janux Therapeutics Inc stocks. The insider ownership of Janux Therapeutics Inc is 16.29%, while institutional ownership is 110.18%. The most recent insider transaction that took place on May 01 ’25, was worth 106,745. In this transaction Chief Business Officer of this company sold 3,333 shares at a rate of $32.03, taking the stock ownership to the 82,139 shares. Before that another transaction happened on May 01 ’25, when Company’s Officer proposed sale 3,333 for $33.20, making the entire transaction worth $110,656.
Janux Therapeutics Inc (JANX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -52.21% per share during the next fiscal year.
Janux Therapeutics Inc (NASDAQ: JANX) Trading Performance Indicators
You can see what Janux Therapeutics Inc (JANX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 58.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 167.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.36, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -2.49 in one year’s time.
Technical Analysis of Janux Therapeutics Inc (JANX)
Analysing the last 5-days average volume posted by the [Janux Therapeutics Inc, JANX], we can find that recorded value of 0.95 million was lower than the volume posted last year of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 79.29%.
During the past 100 days, Janux Therapeutics Inc’s (JANX) raw stochastic average was set at 33.79%, which indicates a significant decrease from 64.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.30 in the past 14 days, which was lower than the 1.65 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.72, while its 200-day Moving Average is $38.28. Now, the first resistance to watch is $27.92. This is followed by the second major resistance level at $29.45. The third major resistance level sits at $30.50. If the price goes on to break the first support level at $25.34, it is likely to go to the next support level at $24.29. Should the price break the second support level, the third support level stands at $22.76.
Janux Therapeutics Inc (NASDAQ: JANX) Key Stats
There are 59,175K outstanding shares of the company, which has a market capitalization of 1.56 billion. As of now, sales total 10,590 K while income totals -68,990 K. Its latest quarter income was 0 K while its last quarter net income were -20,220 K.